FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981701065> ?p ?o ?g. }

• W2981701065 endingPage "S701" @default.
• W2981701065 startingPage "S701" @default.
• W2981701065 abstract "Oncogenic RET fusions and mutations have been identified in several cancer types including non-small cell lung cancer (NSCLC), papillary thyroid cancer and medullary thyroid cancer. Current treatment of RET-altered cancers is generally limited to multikinase inhibitors (MKIs) designed to target other kinases, and chemotherapy, which often have limited efficacy and carry significant off-target toxicities. BLU-667 is an investigational oral precision therapy that is a potent and highly selective inhibitor of oncogenic RET fusions and mutations (IC50 = 0.4 nM) and has demonstrated tumor growth inhibition and RET signaling abrogation in numerous subcutaneous models of RET-driven disease (Subbiah et al. 2018). Early phase 1 results with BLU-667 have demonstrated promising clinical activity in both RET fusion and RET mutant-driven tumors. As brain metastases occur in up to half of patients with NSCLC, we developed several preclinical intracranial models of RET-driven disease and demonstrate robust activity of BLU-667 in this setting. KIF5b-RET-Ba/F3 cells engineered to express luciferase or CCDC6-RET CRC PDX tumors were implanted intracranially in Balb/c nude mice. Efficacy was determined by survival or imaging after luciferin tail vein injection. Pharmacodynamic confirmation of RET kinase inhibition was assessed by immunoblot or qRT-PCR of RET pathway transcriptional markers DUSP6 and SPRY4 in harvested tumors. In RET fusion-driven intracranial mouse tumor models, oral BLU-667 treatment demonstrated significant survival benefit at well tolerated doses. This benefit occurred with BLU-667 doses (10 or 30 mg/kg BID) also shown to be efficacious in subcutaneous RET-driven tumor models and at drug exposures below those achieved at the recommended phase 2 dose in humans (400 mg) established in the BLU-667 phase 1 clinical trial. BLU-667 activity was consistent in both KIF5b-RET and CCDC6-RET fusions, the most common RET fusions found in NSCLC. Pharmacodynamic analysis of intracranial tumor tissue after BLU-667 treatment confirmed dose dependent inhibition of RET pathway signaling (P-RET, P-SHC) and >90% downregulation DUSP6 and SPRY4, consistent with full pathway inhibition. In intracranial Ba/F3-KIF5b-RET tumors expressing luciferase, imaging analysis established near complete inhibition of tumor growth in mice treated with BLU-667. In intracranial tumor models driven by KIF5b-RET or CCDC6-RET fusions, BLU-667 inhibits RET kinase activity and increases survival. These data suggest BLU-667 has promise as an investigational agent for RET fusion NSCLC with or without brain metastasis. As such, BLU-667 is currently being evaluated in a clinical trial for patients with RET-driven solid tumors including NSCLC (NCT03037385) with registrational intent." @default.
• W2981701065 created "2019-11-01" @default.
• W2981701065 creator A5010844468 @default.
• W2981701065 creator A5017360327 @default.
• W2981701065 creator A5044798069 @default.
• W2981701065 creator A5067471098 @default.
• W2981701065 creator A5084316997 @default.
• W2981701065 date "2019-10-01" @default.
• W2981701065 modified "2023-10-13" @default.
• W2981701065 title "P2.03-44 BLU-667 Demonstrates Robust Activity in RET Fusion-Driven Intracranial Tumor Models" @default.
• W2981701065 doi "https://doi.org/10.1016/j.jtho.2019.08.1491" @default.
• W2981701065 hasPublicationYear "2019" @default.
• W2981701065 type Work @default.
• W2981701065 sameAs 2981701065 @default.
• W2981701065 citedByCount "11" @default.
• W2981701065 countsByYear W29817010652020 @default.
• W2981701065 countsByYear W29817010652021 @default.
• W2981701065 countsByYear W29817010652022 @default.
• W2981701065 countsByYear W29817010652023 @default.
• W2981701065 crossrefType "journal-article" @default.
• W2981701065 hasAuthorship W2981701065A5010844468 @default.
• W2981701065 hasAuthorship W2981701065A5017360327 @default.
• W2981701065 hasAuthorship W2981701065A5044798069 @default.
• W2981701065 hasAuthorship W2981701065A5067471098 @default.
• W2981701065 hasAuthorship W2981701065A5084316997 @default.
• W2981701065 hasBestOaLocation W29817010651 @default.
• W2981701065 hasConcept C121608353 @default.
• W2981701065 hasConcept C126322002 @default.
• W2981701065 hasConcept C143998085 @default.
• W2981701065 hasConcept C150903083 @default.
• W2981701065 hasConcept C184235292 @default.
• W2981701065 hasConcept C207001950 @default.
• W2981701065 hasConcept C2776694085 @default.
• W2981701065 hasConcept C2779761222 @default.
• W2981701065 hasConcept C2780120053 @default.
• W2981701065 hasConcept C2781461381 @default.
• W2981701065 hasConcept C502942594 @default.
• W2981701065 hasConcept C71924100 @default.
• W2981701065 hasConcept C86803240 @default.
• W2981701065 hasConcept C95444343 @default.
• W2981701065 hasConceptScore W2981701065C121608353 @default.
• W2981701065 hasConceptScore W2981701065C126322002 @default.
• W2981701065 hasConceptScore W2981701065C143998085 @default.
• W2981701065 hasConceptScore W2981701065C150903083 @default.
• W2981701065 hasConceptScore W2981701065C184235292 @default.
• W2981701065 hasConceptScore W2981701065C207001950 @default.
• W2981701065 hasConceptScore W2981701065C2776694085 @default.
• W2981701065 hasConceptScore W2981701065C2779761222 @default.
• W2981701065 hasConceptScore W2981701065C2780120053 @default.
• W2981701065 hasConceptScore W2981701065C2781461381 @default.
• W2981701065 hasConceptScore W2981701065C502942594 @default.
• W2981701065 hasConceptScore W2981701065C71924100 @default.
• W2981701065 hasConceptScore W2981701065C86803240 @default.
• W2981701065 hasConceptScore W2981701065C95444343 @default.
• W2981701065 hasIssue "10" @default.
• W2981701065 hasLocation W29817010651 @default.
• W2981701065 hasOpenAccess W2981701065 @default.
• W2981701065 hasPrimaryLocation W29817010651 @default.
• W2981701065 hasRelatedWork W1976985375 @default.
• W2981701065 hasRelatedWork W2028411003 @default.
• W2981701065 hasRelatedWork W2046572122 @default.
• W2981701065 hasRelatedWork W2092948006 @default.
• W2981701065 hasRelatedWork W2104909431 @default.
• W2981701065 hasRelatedWork W2791728205 @default.
• W2981701065 hasRelatedWork W2968350930 @default.
• W2981701065 hasRelatedWork W3022228189 @default.
• W2981701065 hasRelatedWork W3134757250 @default.
• W2981701065 hasRelatedWork W4220834124 @default.
• W2981701065 hasVolume "14" @default.
• W2981701065 isParatext "false" @default.
• W2981701065 isRetracted "false" @default.
• W2981701065 magId "2981701065" @default.
• W2981701065 workType "article" @default.